28.6 F
New York
Thursday, January 28, 2021

CEL-SCI Corporation (NYSEMKT:CVM) Provides Update on Phase 3 Hold

Must read

Artificial Intelligence Technology Solutions (OTCMKTS:AITX) Posts Major Gains on Breakout

The artificial intelligence industry has grown at a remarkable rate over the past half a decade or so and it is expected...

American Battery Metals Corp (OTCMKTS:ABML) Hitting Key Milestones

Over the course of the past week, American Battery Metals Corp (OTCMKTS:ABML) has been in focus among investors after the company announced...

American Green Inc (OTCMKTS:ERBB) Stock Gains Momentum on Amazon News

One of the more interesting operators in the cannabis space in 2020 is American Green Inc (OTCMKTS:ERBB), and this week, the company...

DSG Global Inc (OTCMKTS:DSGT) Hits Multi-Month High On Sudden Optimism

DSG Global Inc (OTCMKTS:DSGT) has been in the news over the past week or so after the company placed large orders through...
CEL-SCI Corporation (NYSEMKT:CVM) has had some issues internally with the arbitration case against the former CRO that originally ran the Phase 3 trial. CEL-SCI made the high for the year back in Jan, testing the .16 cent level. CVM shares then fell back in late April, as the news of the trial started to filter through to the stock. So that brings us to where we are today.
The company gave an update on clinical hold communications with the U.S. Food and Drug Administration regarding the partial clinical hold of CEL-SCI’s Phase 3 clinical trial of its drug Multikine* (Leukocyte Interleukin, Injection). The drug targets patients with squamous cell carcinoma of the head and neck.
CEL-SCI Corporation (NYSEMKT:CVM) said the partial clinical hold on this ongoing Phase 3 head and neck cancer trial with 928 patients covered a range of issues previously described to the shareholders. Following a Type A meeting with the FDA, CVM filed a response that was intended to address all of these issues. As part of the response to address the concerns, they submitted a proposed update to the Investigator’s Brochure (IB) and a proposed “Dear Investigator” letter which was planned to follow the FDA’s review and approval. In its most recent communication, the FDA stated: “We have completed the review of your submission and have concluded that removal of the clinical hold is not warranted.”
Find out when $CVM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

The FDA’s response directed that: 1) The IB and the “Dear investigator” letter should contain specific statements and data which were not included in the proposed texts we had submitted in April 2017 and 2) Some of the statements that were included in the proposed texts accompanying our April 2017 response should be removed. Work on revising the IB and the “Dear Investigator” letter in accordance with the FDA’s directions has already begun and CVM intends to resubmit the amended documents to the FDA for their review and approval soon.

In the Agency’s May 2017 letter, the FDA also stated: “Until you have submitted the required information and we notify you that you may initiate clinical studies, this IND remains on clinical hold and you may not legally initiate or resume clinical studies under it.” The heading on the FDA May 2017 letter is “Continue Full Clinical Hold”, whereas the heading on previous hold letters was “Partial Clinical Hold”.

The FDA communicated to CVM that the IND is on Full Clinical Hold because the exception to the full hold no longer exists, since all patients had completed planned treatment with our product, Multikine. Placing the IND on full hold does not result in termination of the Phase 3 head and neck cancer trial and all protocol-specified data collection will continue as described in the protocol, but CVM may not enroll new patients and may not resume dosing in any previously enrolled patient.

In the Agency’s recent letter, the FDA stated, “Finally, since there are no patients currently receiving Multikine under this IND and the only study being conducted under this IND (Study CA001P3) is closed to accrual, we have concluded that all studies covered by this IND must be placed on clinical hold; proposed studies may not be initiated, and ongoing studies are suspended.” It should be noted that, at present, CEL-SCI is not conducting other studies with Multikine under this IND other than the ongoing Phase 3 study, which is subject to the clinical hold, no other studies are planned in the immediate future, and an amendment to the Phase 3 head and neck cancer study will be filed only if required. The study investigating the use of Multikine as a potential treatment in HPV-related disease is being conducted under a different IND.

CEL-SCI Corporation (NYSE MKT:CVM) said they are continuing to work extremely hard to bring the Phase 3 trial to a successful conclusion, to have the FDA’s clinical hold lifted, and to win the arbitration case against the former CRO that originally ran the Phase 3 trial. Shareholders have been patient here (so far) and look for the company to move forward with Multikine and ground-breaking solutions for patients with squamous cell carcinoma of the head and neck. This may be a very interesting story in the near term, and we will look forward to updating it again soon. For more news on CVM and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.

Latest article

Sun Pacific Holding Corp (OTCMKTS:SNPW) Stock Rockets and Crashes. What’s Next?

Sometimes certain stocks move in a big way without any development or news and although it remains a mystery for investors, it...

Bombardier, Inc. (OTCMKTS:BDRBF) Uptrend at Risk: In Focus

British company Bombardier, Inc. (OTCMKTS:BDRBF) came into sharp focus among investors last week after a significant development. Major Triggers

American Battery Metals Corp (OTCMKTS:ABML) Points up on Surge of Momentum

One of the stocks to have seen a lot of action last week was that of American Battery Metals Corp (OTCMKTS:ABML) and...

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Attempts To Rebound On Bullish Note

While the remarkable rally in Bitcoin has led to breathless speculation about its long term price, the recent rally in Grayscale Ethereum...

Sunhydrogen Inc (OTCMKTS:HYSR) Continues to Trend Higher on High Demand

One of the sectors to have come into significant focus among investors in recent times is the hydrogen...